Page last updated: 2024-12-10
2,2'-bipyridyl-6-carbothioamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,2'-bipyridyl-6-carbothioamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3034633 |
CHEMBL ID | 17755 |
SCHEMBL ID | 5997996 |
MeSH ID | M0103358 |
Synonyms (16)
Synonym |
---|
nsc-308938 |
nsc308938 |
78797-02-1 |
6-(2-pyridyl)pyridine-2-carbothioamide |
bpyta |
[2,2'-bipyridine]-6-carbothioamide |
CHEMBL17755 |
6-pyridin-2-ylpyridine-2-carbothioamide |
hq16m0gm8a , |
nsc 308938 |
2,2'-bipyridyl-6-carbothioamide |
(2,2'-bipyridine)-6-carbothioamide |
unii-hq16m0gm8a |
DTXSID10229306 |
SCHEMBL5997996 |
2,2'-bipyridine-6-thioamide |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Of these, only 2,2'-bipyridyl-6-carbothioamide (1a) showed antitumor activity at relatively high dosage levels." | ( N*-N*-S* tridentate ligand system as potential antitumor agents. Antonini, I; Claudi, F; Cristalli, G; Franchetti, P; Grifantini, M; Martelli, S, 1981) | 0.61 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (14)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID153150 | Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 100 mg/kg compound administered | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID97738 | Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 2 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID97737 | Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 1 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID154371 | Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 100 mg/kg compound administered; T/C=1.5/0.5 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID201713 | Growth inhibition of cultured Sarcoma cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 1 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID201712 | Growth inhibition of cultured Sarcoma 180 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 2 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID153152 | Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 400 mg/kg compound administered | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID97735 | Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 1 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID154364 | Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 200 mg/kg compound administered; T/C=1.5/0.5 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID154365 | Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 400 mg/kg compound administered; T/C= -0.8/5 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID201714 | Growth inhibition of cultured Sarcoma cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 2 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID97736 | Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 2 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID153151 | Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 200 mg/kg compound administered | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
AID201711 | Growth inhibition of cultured Sarcoma 180 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 1 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10 | N*-N*-S* tridentate ligand system as potential antitumor agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.94) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |